Tuberc Respir Dis Search

CLOSE


Tuberc Respir Dis > Volume 52(4); 2002 > Article
Tuberculosis and Respiratory Diseases 2002;52(4):376-384.
DOI: https://doi.org/10.4046/trd.2002.52.4.376    Published online April 1, 2002.
The Effect of Steroid Therapy in Patients with Late ARDS.
Jin Won Huh, , Chae Man Lim, , Yang Jin Jegal, , Sang Do Lee, , Woo Sung KIm, , Dong Soon Kim, , Won Dong Kim, , Youn Suck Koh,
Division of Pulmonary and Critical Care Medicine, Asan Medical Center, Univeristy of Ulsan College of medicine, Seoul, Korea. yskoh@amc.seoul.kr
Abstract
BACKGROUND
The mortality from acute respiratory distress syndrome(ARDS) in the late stage, which is characterized by progressive pulmonary fibroproliferation, is >or=80%. Although previous prospective trials failed to show a survival benefit of steroid therapy in early ARDS, recently, a few of reports have described the survival benefit of the long-term use of steroid in patients with late ARDS. In this study, we analyzed the effect of steroid therapy on patietns with late ARDS. In this study, we analyzed the effect of steroid therapy on patients with late ARDS retrospectively in a single. Medral intensive care unit. METHODS: Over a 3-year period, the medical records of 48 ARDS patients who had veen on mechanical ventilation more than 8 days were reviewed. 14 patients were treated by the long-term use of methylprednisolone and another 34 patients served as a control. Both groups were comparable regarding clinical and physiologic data lung injury score(LIS), multiple organ failure score, APACHE III and SAPS II score. Because steroid was instituted after 8 days of advanced mechanical ventilatory support in average, we arbitrarily defined the 8th day of ARDS as first day of the study. RESULTS: Initially, the group had similar PF(PaO2/FiO2)ratio, LIS, APA CHE III and SAPS II score. By 7th day after the start of steroid therapy, there were significant improvements in PF ratio, LIS, APACHE III and SAPS II score. The mortality in the steroid treated group was significantly lower(42.9% vs 73.5%, p<0.05). CONCLUSIONS: Although the data of this study was retrospective and was not randomized, in order to improve the patients's outcomes, steroid therapy should be considered in late ARDS patients. However, prospective trials are needed to define the indication and the effect of steroid therapy in late ARDS.
Key Words: Late ARDS, Methylprednisolone, Survival


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2020 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2community

Close layer
prev next